Roche Holding Aktiengesellschaft operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Roche Holding Aktiengesellschaft with three other
pharmaceutical manufacturers in Europe:
sales of 51.94 billion Swiss Francs [US$52.25 billion]
of which 66%
was Innovative Medicines),
(35.68 billion Euro [US$40.04 billion]
of which 69%
was Pharmaceuticals), and
based in Germany
(39.59 billion Euro [US$44.43 billion]
of which 42%
was Pharmaceuticals & Biological Products).
Roche Holding Aktiengesellschaft reported sales of 56.85 billion Swiss Francs (US$57.19 billion)
December of 2018.
increase of 6.7%
versus 2017, when the company's sales were 53.30 billion Swiss Francs.
Sales at Roche Holding Aktiengesellschaft have increased during each of the previous five years
(and since 2013, sales have increased a total of 22%).
Sales of Pharmaceuticals saw an increase
6.7% in 2018, from
41.22 billion Swiss Francs to 43.97 billion Swiss Francs.